新天地：12月6日召开董事会会议

Group 1 - The company Xintiandi (SZ 301277) announced that its sixth board meeting will be held on December 6, 2025, to review the proposal for amending the "Board Secretary Work Guidelines" [1] - For the first half of 2025, Xintiandi's revenue composition shows that pharmaceutical intermediates account for 98.23%, while other businesses make up 1.77% [1] - As of the report date, Xintiandi's market capitalization is 4.8 billion yuan [1] Group 2 - A report highlighted the first case of pregabalin abuse leading to addiction in China, revealing vulnerabilities in online platforms that allow drug purchases without medical records [1]